Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
53,136,600
-
Number of holders
-
93
-
Total 13F shares, excl. options
-
36,780,532
-
Shares change
-
+531,376
-
Total reported value, excl. options
-
$621,647,079
-
Value change
-
+$3,005,970
-
Put/Call ratio
-
83.92%
-
Number of buys
-
39
-
Number of sells
-
-52
-
Price
-
$16.9
Significant Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q1 2022
115 filings reported holding ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share as of Q1 2022.
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) has 93 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36,780,532 shares
of 53,136,600 outstanding shares and own 69.22% of the company stock.
Largest 10 shareholders include venBio Partners LLC (9,699,925 shares), Vivo Capital, LLC (4,220,048 shares), FMR LLC (3,558,954 shares), Logos Global Management LP (3,011,352 shares), WELLINGTON MANAGEMENT GROUP LLP (2,809,826 shares), STATE STREET CORP (2,133,744 shares), VANGUARD GROUP INC (1,675,656 shares), BlackRock Inc. (1,355,478 shares), Redmile Group, LLC (772,397 shares), and Cormorant Asset Management, LP (712,079 shares).
This table shows the top 93 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.